Faculty profile

Bharati Bapat

Back to faculty

Professor Emeritus/EmeritaDepartment of Laboratory Medicine and PathobiologyUniversity of Toronto

Bharati Bapat

Professor Emeritus/Emerita

Department of Laboratory Medicine and Pathobiology

Temerty Faculty of Medicine

University of Toronto

Toronto, Ontario, Canada

ORCID

Supervision signals

Emeritus professors are retired and rarely take new students.
3 publications in the last five years, latest in 2023.
Senior (last) author on 2 recent papers, a sign of leading a research group.

These signals come from public records, including CIHR, NSERC and SSHRC funding decisions. Ask the professor or the graduate program whether they are taking new students.

Academic metrics

Publications

Citations

h-index

Collaborators

Grants

Publications by year

Counts cover the works listed on the university profile; citation counts come from Dimensions.

Profiles and links

University Profile Search on Google Scholar iDORCID

Find them onX · LinkedIn · Bluesky · YouTube

Signals and details

Research

Read how they describe their research on their University of Toronto profile.

Cancer genetics Cancer molecular targets Epigenetics and epigenomics Cancer Cancer diagnosis

Latest papers

Helicobacter pylori Status May Differentiate Two Distinct Pathways of Gastric Adenocarcinoma Carcinogenesis.
Current oncology (Toronto, Ont.) · 2023
A novel methylated cell-free DNA marker panel to monitor treatment response in metastatic prostate cancer.
Epigenomics · 2022 · senior author
Combining CAPRA-S With Tumor IDC/C Features Improves the Prognostication of Biochemical Recurrence in Prostate Cancer Patients.
Clinical genitourinary cancer · 2022 · senior author

All 79 publications

Latest funding

Feasibility of integrating epigenomic and genomic liquid biopsy biomarkers into the clinical management of advanced prostate cancer
CIHR · 2018 · Co-investigator
$544,120
Genetic, Epigenetic and Proteomic Analysis of the Kallikrein Family in Search for Novel Diagnostic Prognostic and Risk Susceptibility Algorithms for Prostate Cancer
CIHR · 2009 · Co-investigator
$599,728
Genetic, Epigenetic and Proteomic Analysis of the Kallikrein Family in Search for Novel Diagnostic Prognostic and Risk Susceptibility Algorithms for Prostate Cancer
CIHR · 2008 · Co-investigator
$100,000

All 4 grants and awards

79 publications.

Helicobacter pylori Status May Differentiate Two Distinct Pathways of Gastric Adenocarcinoma Carcinogenesis.

Tobi M, Weinstein D, Kim M, Hatfield J, Sochacki P, Levi E, An T, Hamre M, Tolia V, Fligiel S, Marepally R, Hallman J, Bapat B, Yuan M, McVicker B, Gallinger S

Current oncology (Toronto, Ont.)2023

DOI: 10.3390/curroncol30090578 PMID: 37754493

A novel methylated cell-free DNA marker panel to monitor treatment response in metastatic prostate cancer.

Peter MR, Bilenky M, Shi Y, Pu J, Kamdar S, Hansen AR, Fleshner NE, Sridhar SS, Joshua AM, Hirst M, Xu W, Bapat B

Epigenomics2022Senior author

DOI: 10.2217/epi-2022-0103 PMID: 35818933

Combining CAPRA-S With Tumor IDC/C Features Improves the Prognostication of Biochemical Recurrence in Prostate Cancer Patients.

Jeyapala R, Kamdar S, Olkhov-Mitsel E, Zlotta A, Fleshner N, Visakorpi T, van der Kwast T, Bapat B

Clinical genitourinary cancer2022Senior author

DOI: 10.1016/j.clgc.2022.01.003 PMID: 35151601

Investigating Urinary Circular RNA Biomarkers for Improved Detection of Renal Cell Carcinoma.

Peter MR, Zhao F, Jeyapala R, Kamdar S, Xu W, Hawkins C, Evans AJ, Fleshner NE, Finelli A, Bapat B

Frontiers in oncology2021Senior author

DOI: 10.3389/fonc.2021.814228 PMID: 35174071

Distinct DNA methylation patterns associated with treatment resistance in metastatic castration resistant prostate cancer.

Peter MR, Bilenky M, Davies A, Isserlin R, Bader GD, Fleshner NE, Hirst M, Zoubeidi A, Bapat B

Scientific reports2021Senior author

DOI: 10.1038/s41598-021-85812-3 PMID: 33758253

A 38-gene model comprised of key TET2-associated genes shows additive utility to high-risk prostate cancer cases in the prognostication of biochemical recurrence.

Kamdar S, Fleshner NE, Bapat B

BMC cancer2020Senior author

DOI: 10.1186/s12885-020-07438-4 PMID: 33008340

Dynamics of the cell-free DNA methylome of metastatic prostate cancer during androgen-targeting treatment.

Peter MR, Bilenky M, Isserlin R, Bader GD, Shen SY, De Carvalho DD, Hansen AR, Hu P, Fleshner NE, Joshua AM, Hirst M, Bapat B

Epigenomics2020Senior author

DOI: 10.2217/epi-2020-0173 PMID: 32867540

A noninvasive urine-based methylation biomarker panel to detect bladder cancer and discriminate cancer grade.

Hermanns T, Savio AJ, Olkhov-Mitsel E, Mari A, Wettstein MS, Saba K, Bhindi B, Kuk C, Poyet C, Wild PJ, Noon A, Bashir S, Juvet T, Rendon RA, Waltregny D, van der Kwast T, Finelli A, Kulkarni GS, Fleshner NE, Lo K, Bapat B, Zlotta AR

Urologic oncology2020

DOI: 10.1016/j.urolonc.2020.01.007 PMID: 32081560

Development of a multivariable risk model integrating urinary cell DNA methylation and cell-free RNA data for the detection of significant prostate cancer.

Connell SP, O'Reilly E, Tuzova A, Webb M, Hurst R, Mills R, Zhao F, Bapat B, Cooper CS, Perry AS, Clark J, Brewer DS

The Prostate2020

DOI: 10.1002/pros.23968 PMID: 32153047

Urinary biomarkers in prostate cancer: to the miRnome and beyond.

Hoey C, Jeyapala R, Boutros PC, Bapat B, Liu SK

Translational andrology and urology2020

DOI: 10.21037/tau.2019.11.25 PMID: 32420197

Profile data last refreshed on September 25, 2026 from the university directory, publication records and CIHR, NSERC and SSHRC funding.

Something wrong or missing on this profile? Suggest a correction

Bharati Bapat

Research

Latest papers

Latest funding

Helicobacter pylori Status May Differentiate Two Distinct Pathways of Gastric Adenocarcinoma Carcinogenesis.

A novel methylated cell-free DNA marker panel to monitor treatment response in metastatic prostate cancer.

Combining CAPRA-S With Tumor IDC/C Features Improves the Prognostication of Biochemical Recurrence in Prostate Cancer Patients.

Investigating Urinary Circular RNA Biomarkers for Improved Detection of Renal Cell Carcinoma.

Distinct DNA methylation patterns associated with treatment resistance in metastatic castration resistant prostate cancer.

A 38-gene model comprised of key TET2-associated genes shows additive utility to high-risk prostate cancer cases in the prognostication of biochemical recurrence.

Dynamics of the cell-free DNA methylome of metastatic prostate cancer during androgen-targeting treatment.

A noninvasive urine-based methylation biomarker panel to detect bladder cancer and discriminate cancer grade.

Development of a multivariable risk model integrating urinary cell DNA methylation and cell-free RNA data for the detection of significant prostate cancer.

Urinary biomarkers in prostate cancer: to the miRnome and beyond.

Feasibility of integrating epigenomic and genomic liquid biopsy biomarkers into the clinical management of advanced prostate cancer

Genetic, Epigenetic and Proteomic Analysis of the Kallikrein Family in Search for Novel Diagnostic Prognostic and Risk Susceptibility Algorithms for Prostate Cancer

Genetic, Epigenetic and Proteomic Analysis of the Kallikrein Family in Search for Novel Diagnostic Prognostic and Risk Susceptibility Algorithms for Prostate Cancer

Genetic and Epigenetic Causes of Male Infertility

Frequent collaborators

Neil Fleshner

Steven Gallinger

Laurent Briollais

Aaron Pollett

Andrew Loblaw

Antonio Finelli

Martin Hirst

Michelle Cotterchio

Wei Xu

Guangju Zhai

Vasundara Venkateswaran

Alexandre Zlotta

Sevtap Savas

Jenna Sykes

Gary Bader

Stanley Liu

Yun-Hee Choi

Cynthia Hawkins

Jehonathan Pinthus

Amina Zoubeidi